Jiang, Z., Zhang, Y., Yang, Y., Yue, Z., & Pan, Z. (2018). Efficacy of pemetrexed and carboplatin with or without bevacizumab in lung adenocarcinoma patients with EGFR non‐T790M mutations after progression on first‐line EGFR‐tyrosine kinase inhibitors. Thorac Cancer.
シカゴスタイル引用形Jiang, Zhansheng, Yu Zhang, Yinli Yang, Zhensong Yue, , Zhanyu Pan. "Efficacy of Pemetrexed and Carboplatin With or Without Bevacizumab in Lung Adenocarcinoma Patients With EGFR Non‐T790M Mutations After Progression On First‐line EGFR‐tyrosine Kinase Inhibitors." Thorac Cancer 2018.
MLA引用形式Jiang, Zhansheng, et al. "Efficacy of Pemetrexed and Carboplatin With or Without Bevacizumab in Lung Adenocarcinoma Patients With EGFR Non‐T790M Mutations After Progression On First‐line EGFR‐tyrosine Kinase Inhibitors." Thorac Cancer 2018.